Question explored with the scientific record
How can a flu vaccine trigger warm aiha?
The short version: the evidence retrieved does not contain a single study that directly tests whether flu vaccination can trigger warm autoimmune hemolytic anemia (wAIHA), so the question remains unanswered by the data we have.
The evidence you provided covers many things: mouse immune responses to flu vaccines [1], vaccine uptake surveys [2], vaccine effectiveness in children [3, 5, 6], and several studies on wAIHA itself [12, 13, 14, 18, 20, 21]. But none of the wAIHA studies examine vaccination as a trigger. The wAIHA papers describe the disease's mechanisms, treatment patterns, and associated conditions like cancer [25] or hypereosinophilic syndrome [22], but they do not list flu shots as a cause. The flu vaccine studies, meanwhile, measure antibody titers and infection rates, not autoimmune hemolysis.
The mechanism you propose—post-vaccination immune dysregulation leading to autoantibodies against red blood cells—is biologically plausible. Vaccines are designed to provoke a strong immune response, and any strong immune stimulus can, in theory, trigger autoimmunity in a susceptible person. The literature on other vaccines (like the COVID-19 mRNA shots and myocarditis [30], or adenoviral vaccines and VITT [27]) shows that vaccine-triggered autoimmune phenomena are real. But for flu vaccine and wAIHA specifically, the evidence you retrieved is silent. No study in this set compared wAIHA rates between vaccinated and unvaccinated populations, or followed vaccinated cohorts for autoimmune hemolysis.
My call: the evidence does not establish that flu vaccine can trigger wAIHA, but it also does not rule it out. The most informative study design—vaccinated versus unvaccinated over time with hemolytic anemia as an endpoint—was never run. Confidence: low, because the question was never studied, not because it was studied and found safe.
Sources examined 32
-
Cell-Cultured Influenza Vaccine Enhances IFN-γ+ T Cell and Memory T Cell Responses Following A/Victoria/2570/2019 IVR-215 (A/H1N1) Infection
This study compares the immune responses elicited by cell-cultured and egg-based influenza vaccines in BALB/c mice, demonstrating that the cell-cultured vaccine significantly enhances T cell responses and offers potential advantages for long-term immunity.
DOI: 10.3390/vaccines12121392 -
Low uptake of influenza vaccine among university students: Evaluating predictors beyond cost and safety concerns
This study evaluates the low uptake of influenza vaccination among university students, identifying barriers to vaccination and the potential impact of educational interventions on increasing vaccine acceptance.
DOI: 10.1016/j.vaccine.2015.02.033 -
Superior Relative Efficacy of Live Attenuated Influenza Vaccine Compared With Inactivated Influenza Vaccine in Young Children With Recurrent Respiratory Tract Infections
A multicenter, randomized phase III trial in 6- to 71-month-old children with recurrent respiratory tract infections shows that cold-adapted influenza vaccine, trivalent (CAIV-T) provides superior protection against culture-confirmed influenza strains antigenically similar to th…
DOI: 10.1097/01.inf.0000237829.66310.85 -
Influenza Virus: Global Health Impact, Strategies, Challenges, Role of Nanotechnolgy in Influenza Vaccine Development
A comprehensive, up-to-date review of the global health impact of influenza, current vaccination strategies, and the evolving role of nanotechnology in influenza vaccine development, including challenges and future directions toward universal vaccines.
DOI: 10.3390/vaccines13090890 -
Effectiveness of Live Attenuated vs Inactivated Influenza Vaccines in Children During the 2012-2013 Through 2015-2016 Influenza Seasons in Alberta, Canada
This study compares the effectiveness of live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) in preventing laboratory-confirmed influenza among children aged 2 to 17 years during the 2012-2013 to 2015-2016 influenza seasons in Alberta, Canada, findin…
DOI: 10.1001/jamapediatrics.2018.1514 -
The effectiveness of influenza vaccination in preventing hospitalisation in children in Western Australia
This study evaluates the effectiveness of the trivalent inactivated influenza vaccine (TIV) in preventing hospitalizations due to laboratory-confirmed influenza in children in Western Australia, finding a vaccine effectiveness of 62.3% with low vaccine uptake.
DOI: 10.1016/j.vaccine.2015.10.122 -
Induction of Cross-Neutralizing Antibody Against H5N1 Virus After Vaccination with Seasonal Influenza Vaccine in COPD Patients
This study investigates the induction of cross-neutralizing antibodies against the H5N1 virus in elderly COPD patients following vaccination with a seasonal influenza vaccine, revealing that vaccination, rather than influenza illness, is responsible for the observed antibody res…
DOI: 10.1089/vim.2009.0082 -
Influenza vaccine effectiveness against influenza-associated hospitalization in 2015/16 season, Beijing, China
This study estimates the effectiveness of the influenza vaccine against hospitalization due to influenza in Beijing during the 2015/16 season, finding that vaccination did not provide effective protection.
DOI: 10.1016/j.vaccine.2017.03.084 -
Kinetics of viral shedding and immune responses in adults following administration of cold-adapted influenza vaccine
This study investigates the kinetics of viral shedding and immune responses in healthy adults following administration of the cold-adapted influenza vaccine (CAIV), revealing significant viral shedding and immune activation compared to the trivalent influenza vaccine (TIV).
DOI: 10.1016/j.vaccine.2009.09.041 -
Safety of Simultaneous Vaccination With Adjuvanted Zoster Vaccine and Adjuvanted Influenza Vaccine
A randomized, blinded clinical trial in adults aged 65 and older found that simultaneous vaccination with the adjuvanted recombinant zoster vaccine (RZV) and an adjuvanted influenza vaccine (aIIV4) has noninferior safety compared with simultaneous vaccination of RZV and high‑dos…
DOI: 10.1001/jamanetworkopen.2024.40817 -
Evaluation of influenza vaccination in health-care workers, using rapid antigen detection test
This study assesses the effectiveness of the trivalent influenza vaccine in preventing influenza and reducing absenteeism among health-care workers at Gifu Red Cross Hospital, demonstrating significant reductions in both influenza infections and work absenteeism among vaccinated…
DOI: 10.1007/s10156-005-0424-9 -
Content validity and meaningful change for the FACIT-Fatigue scale in warm autoimmune hemolytic anemia: results from qualitative interview studies with patients
This study investigates the content validity of the FACIT-Fatigue scale in patients with warm autoimmune hemolytic anemia (wAIHA) through qualitative interviews, revealing that fatigue is the primary symptom affecting patients' quality of life and that the FACIT-Fatigue is relev…
DOI: 10.1186/s41687-025-00930-0 -
Altered antibody repertoires of plasma IgM and IgG toward nonself antigens in patients with warm autoimmune hemolytic anemia
The study shows that patients with warm autoimmune hemolytic anemia (WAIHA) have broadly altered plasma antibody repertoires toward nonself antigens, characterized by markedly reduced IgM reactivity and distinct IgG patterns compared with healthy controls, with immunosuppressive…
DOI: 10.1016/s0198-8859(01)00225-7 -
Treatment patterns and outcomes among warm autoimmune hemolytic anemia patients receiving rituximab in the United States: A retrospective database study
Real-world US data show rituximab was used in about 29% of warm autoimmune hemolytic anemia patients, most receiving a single cycle, with relapse and hospitalization events common within a year.
DOI: 10.1182/blood-2025-4459 -
Second-Line Therapy Sequencing in Primary Warm Autoimmune Hemolytic Anemia: Splenectomy-Rituximab Versus Rituximab-Splenectomy
A Markov-model health-economic analysis compares second-line sequencing options for adult primary warm autoimmune hemolytic anemia, finding splenectomy-then-rituximab and rituximab-then-splenectomy yield similar lifetime costs and QALYs with no clear advantage under current vacc…
DOI: 10.1182/blood-2023-189957 -
FcRn Blockade as a Targeted Therapeutic Strategy in Antibody-Mediated Autoimmune Diseases: A Focus on Warm Autoimmune Hemolytic Anemia
A comprehensive review of FcRn blockade as a targeted therapeutic strategy for IgG-driven autoimmune diseases, focusing on warm autoimmune hemolytic anemia (wAIHA) and the clinical development of Nipocalimab and other FcRn inhibitors, their mechanisms, trial results, safety, and…
DOI: 10.3390/antib14030065 -
Autoimmune Hemolytic Anemia in Pregnancy
A case report describing a pregnant woman with warm autoimmune hemolytic anemia due to a warm autoantibody with an underlying alloantibody (anti-E), detailing diagnostic workup, transfusion strategies with antigen-matched units and steroids, and favorable maternal–fetal outcomes.
DOI: 10.1309/lmxjo5ty9no1 -
Warm Autoimmune Hemolytic Anemia
This paper provides a comprehensive overview of Warm Autoimmune Hemolytic Anemia (AIHA), detailing its classification, clinical presentation, diagnostic criteria, underlying mechanisms, associated conditions, and treatment options.
DOI: 10.1016/j.hoc.2015.01.001 -
Therapeutic plasma exchange in refractory warm autoimmune hemolytic anemia
This study reports on a case of a 59-year-old man with refractory warm autoimmune hemolytic anemia who underwent therapeutic plasma exchange, highlighting the challenges and outcomes associated with the procedure.
DOI: 10.1111/trf.13932 -
A randomized and double‐blind controlled trial evaluating the safety and efficacy of rituximab for warm auto‐immune hemolytic anemia in adults (the RAIHA study)
This phase 3 multicenter randomized double-blind placebo-controlled trial demonstrated that rituximab combined with prednisone significantly improves the overall response rate in adults with newly diagnosed warm autoimmune hemolytic anemia compared to placebo.
DOI: 10.1002/ajh.24570 -
Venous thromboembolism related to warm autoimmune hemolytic anemia: A case–control study
This study investigates the frequency, presentation, and risk factors for venous thromboembolism (VTE) in patients with warm autoimmune hemolytic anemia (wAIHA), finding that 20% of patients experienced VTE, primarily during severe hemolytic flares, and emphasizes the need for V…
DOI: 10.1016/j.autrev.2015.07.001 -
Hypereosinophilic Syndrome with Eosinophilic Myocarditis and Coexisting Autoimmune Hemolytic Anemia: A Case Report
63-year-old Japanese woman with idiopathic hypereosinophilic syndrome presenting eosinophilic myocarditis and coexisting warm autoimmune hemolytic anemia, rapidly improving with prednisolone and warfarin and showing resolution of left ventricular apical thrombus and normalizatio…
DOI: 10.2169/internalmedicine.6915-25 -
Flow cytometric determination of RBC survival in autoimmune hemolytic anemia
This study presents a flow cytometric technique for determining the survival of transfused and autologous red blood cells (RBCs) in a patient with warm autoimmune hemolytic anemia (WAIHA), highlighting the method's advantages over traditional radioactive labeling.
DOI: 10.1046/j.1537-2995.2001.41040493.x -
Autoimmune haemolytic anaemia in childhood associated with non‐complement binding IgM autoantibodies
Non-complement-binding IgM autoantibodies bound to circulating red blood cells can cause warm autoimmune hemolytic anemia in children, often with DAT negativity, indicating a complement-independent mechanism of RBC destruction.
DOI: meta/10.1111/j.1365-2141.1987.tb06137.x -
Autoimmune hemolytic anemia associated with renal urothelial cancer: A case report and literature review
This case report describes a 52-year-old man with warm autoimmune hemolytic anemia (AIHA) associated with renal urothelial cancer who achieved temporary hematologic improvement after nephroureterectomy, highlighting a rare paraneoplastic presentation and its clinical management.
DOI: 10.1186/s12894-015-0071-0 -
Impact of genotypic variability of measles virus T-cell epitopes on vaccine-induced T-cell immunity
This study investigates the impact of genotypic variability of measles virus T-cell epitopes on vaccine-induced T-cell immunity, revealing that mutations in epitope regions can significantly impair the effectiveness of vaccine-induced CD4+ T-cell responses.
DOI: 10.1038/s41541-025-01088-y -
Vaccine-induced thrombotic thrombocytopenia (VITT): first report from India
This study reports the first cases of vaccine-induced thrombotic thrombocytopenia (VITT) in India, detailing the clinical presentations, management, and outcomes of two young male patients following ChAdOx1 nCoV-19 vaccination.
DOI: 10.1186/s12959-022-00370-6 -
Addition of N-glycosylation sites on the globular head of the H5 hemagglutinin induces the escape of highly pathogenic avian influenza A H5N1 viruses from vaccine-induced immunity
This study investigates how the addition of N-glycosylation sites on the hemagglutinin of H5N1 avian influenza viruses can induce escape from vaccine-induced immunity, demonstrating that a single additional glycosite significantly contributes to this immune evasion.
DOI: 10.1016/j.virol.2015.08.033 -
Impact of p53-based immunization on primary chemically-induced tumors
In a mouse model of chemically induced primary tumors, p53-based DNA and dendritic cell vaccines induce WT-p53–specific CTLs but drive immunoselection, leading to epitope loss and MHC downregulation in outgrowing tumors and only modest protection against carcinogenesis.
DOI: 10.1002/ijc.20686 -
Determinants of COVID-19 vaccine-induced myocarditis
A VAERS-based analysis describing the characteristics and determinants of COVID-19 vaccine–induced myocarditis, highlighting a higher risk in young males after dose 2 and a temporal clustering of events following vaccination.
DOI: 10.1177/20420986241226566 -
HPV 18 antibody levels, clinical efficacy and induced immune memory: A trio?
This study examines the long-term seroconversion rates and immune memory associated with HPV vaccination, highlighting the potential limitations in understanding vaccine-induced protection due to insufficient follow-up time and the complexities of natural immunity.
DOI: 10.1016/j.vaccine.2009.07.009 -
An influenza A/H3 outbreak during the 2004/2005 winter in elderly vaccinated people living in a nursing home
This study investigates the immune response and effectiveness of the 2004/2005 influenza vaccine in preventing an outbreak of the A/H3N2 drift variant among elderly residents in a nursing home, revealing that while vaccination induced adequate antibody responses, it failed to pr…
DOI: 10.1016/j.vaccine.2006.05.037